Proportion of individuals at high 10-year risk for a CVD event by each algorithm who self-report as being under clinical management (%), AWI-Gen baseline data
| Framingham (office) | Framingham (lab) | Globorisk (office) | Globorisk (lab) | WHO-CVD (office) | WHO-CVD (lab) | |
| Agincourt | ||||||
| Men | 47/107 (43.9) | 23/49 (46.9) | 19/62 (30.6) | 16/45 (35.6) | 1/1 (100) | 1/1 (100) |
| Women | 32/45 (71.1) | 17/24 (70.8) | 9/21 (42.9) | 7/11 (63.6) | 0/0 | 0/0 |
| All | 79/152 (52.0) | 40/73 (54.8) | 28/83 (33.7) | 23/56 (41.1) | 1/1 (100) | 1/1 (100) |
| Dikgale | ||||||
| Men | 29/92 (31.5) | 21/52 (40.4) | 7/37 (18.9) | 11/34 (32.4) | 0/0 | 0/0 |
| Women | 24/32 (70.6) | 12/19 (63.2) | 3/13 (23.1) | 7/14 (50.0) | 0/0 | 0/0 |
| All | 53/126 (42.1) | 33/71 (46.5) | 10/50 (20.0) | 18/48 (37.5) | 0/0 | 0/0 |
| Nairobi | ||||||
| Men | 13/72 (18.1) | 10/41 (24.4) | 0/2 (0) | 0/4 (0) | 0/1 (0) | 0/2 (0) |
| Women | 14/18 (77.8) | 7/8 (87.5) | 0/0 | 0/0 | 0/0 | 0/0 |
| All | 27/90 (30.0) | 1749/ (34.7) | 0/2 (0) | 0/4 (0) | 0/1 (0) | 0/2 (0) |
| Nanoro | ||||||
| Men | 15/45 (33.3) | 7/19 (36.8) | 3/8 (37.5) | 0/6 (0) | 0/0 | 0/0 |
| Women | 3/3 (100) | 1/1 (100) | 0/0 | 0/0 | 0/0 | 0/0 |
| All | 18/48 (37.5) | 8/20 (40.0) | 3/8 (37.5) | 0/6 (0) | 0/0 | 0/0 |
| Navrongo | ||||||
| Men | 13/122 (10.7) | 5/28 (17.9) | 3/32 (9.4) | 2/26 (7.7) | 0/0 | 0/0 |
| Women | 16/23 (69.6) | 5/8 (62.5) | 10/26 (38.5) | 6/19 (31.6) | 0/0 | 0/0 |
| All | 29/145 (20.0) | 10.36 (27.8) | 13/58 (22.4) | 8/45 (17.8) | 0/0 | 0/0 |
| Soweto | ||||||
| Men | 37/245 (15.1) | 24/140 (17.1) | 13/148 (8.8) | 27/125 (21.6) | 0/3 (0) | 1/1 (100) |
| Overall | ||||||
| Men | 154/683 (22.6) | 90/329 (27.4) | 45/289 (15.6) | 56/240 (23.3) | 1/5 (20.0) | 2/6 (33.3) |
| Women* | 89/123 (72.4) | 42/60 (70.0) | 22/60 (36.7) | 20/44 (45.5) | 0/0 | 0/0 |
| All* | 243/803 (30.2) | 132/389 (33.9) | 67/349 (19.2) | 76/284 (26.8) | 1/5 (20.0) | 2/6 (33.3) |
| % on treatment | <10% | 11%–20% | 21%–40% | 41%–60% | 61%–80% | >81% |
*Excluding Soweto women (due to missing treatment data).
AWI-Gen, Africa-Wits-INDEPTH partnership for Genomic studies; CVD, cardiovascular disease.